BioCentury | Sep 13, 2013
Politics & Policy

NIH rare disease program selects third round of projects

...projects are focused on treating retinitis pigmentosa and include a small molecule pharmacological chaperone from Bikam Pharmaceuticals Inc....
BioCentury | Sep 29, 2008
Product Development

Ophthalmic deals

...excluding cancer. Upfront includes a $3M equity investment and $1.9M in research funding. Mar 08 Bikam/Dalton...
...will use its medicinal chemistry technology to discover several new classes of compounds against undisclosed Bikam...
BioCentury | Mar 10, 2008
Company News

Bikam Inc., Dalton Chemical Laboratories Inc. deal

...technology to discover several new classes of compounds against undisclosed Bikam targets for ophthalmologic indications. Bikam...
...biological assays and delivery methodologies to further develop the compounds. Further terms were not disclosed. Bikam...
Items per page:
1 - 3 of 3
BioCentury | Sep 13, 2013
Politics & Policy

NIH rare disease program selects third round of projects

...projects are focused on treating retinitis pigmentosa and include a small molecule pharmacological chaperone from Bikam Pharmaceuticals Inc....
BioCentury | Sep 29, 2008
Product Development

Ophthalmic deals

...excluding cancer. Upfront includes a $3M equity investment and $1.9M in research funding. Mar 08 Bikam/Dalton...
...will use its medicinal chemistry technology to discover several new classes of compounds against undisclosed Bikam...
BioCentury | Mar 10, 2008
Company News

Bikam Inc., Dalton Chemical Laboratories Inc. deal

...technology to discover several new classes of compounds against undisclosed Bikam targets for ophthalmologic indications. Bikam...
...biological assays and delivery methodologies to further develop the compounds. Further terms were not disclosed. Bikam...
Items per page:
1 - 3 of 3